Michael E Charness Selected Research

Fetal Alcohol Spectrum Disorders

1/2020	Fetal alcohol spectrum disorder predisposes to metabolic abnormalities in adulthood.
1/2019	Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder.
1/2018	L1 coupling to ankyrin and the spectrin-actin cytoskeleton modulates ethanol inhibition of L1 adhesion and ethanol teratogenesis.
11/2014	Effect of lipid raft disruption on ethanol inhibition of l1 adhesion.
4/2013	Mitogen-activated protein kinase modulates ethanol inhibition of cell adhesion mediated by the L1 neural cell adhesion molecule.
11/2012	Ethanol disrupts axon outgrowth stimulated by netrin-1, GDNF, and L1 by blocking their convergent activation of Src family kinase signaling.
5/2011	Two alcohol binding residues interact across a domain interface of the L1 neural cell adhesion molecule and regulate cell adhesion.
1/2011	Effects of ethanol and NAP on cerebellar expression of the neural cell adhesion molecule L1.
1/2008	An alcohol binding site on the neural cell adhesion molecule L1.
10/2006	Maternal oral intake mouse model for fetal alcohol spectrum disorders: ocular defects as a measure of effect.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael E Charness Research Topics

Disease

12	Fetal Alcohol Spectrum Disorders 01/2020 - 07/2003
8	Teratogenesis 01/2020 - 10/2002
2	COVID-19 01/2022 - 01/2021
2	Microphthalmos 12/2007 - 10/2006
1	Overweight 01/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Obesity 01/2020
1	Genetic Predisposition to Disease (Genetic Predisposition) 04/2013
1	Binge Drinking 01/2011
1	Coloboma (Colobomas) 10/2006
1	Anencephaly (Aprosencephaly) 01/2005
1	Neural Tube Defects (Exencephaly) 01/2005
1	Dystonia (Limb Dystonia) 08/2003
1	Dystonic Disorders (Writer's Cramp) 08/2003
1	Muscular Diseases (Myopathy) 08/2003

Drug/Important Bio-Agent (IBA)

13	Ethanol (Ethyl Alcohol)IBA 01/2020 - 10/2002
4	Peptides (Polypeptides)IBA 01/2011 - 10/2002
3	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 11/2014 - 01/2008
2	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 01/2018 - 05/2011
1	AerosolsIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2021
1	VaccinesIBA 01/2021
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	SpectrinIBA 01/2018
1	AnkyrinsIBA 01/2018
1	MAP Kinase Kinase 1IBA 04/2013
1	Netrin-1IBA 11/2012
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 11/2012
1	Proteins (Proteins, Gene)FDA Link 01/2011
1	Peptide Hydrolases (Proteases)FDA Link 06/2004
1	Mitochondrial DNA (mtDNA)IBA 08/2003
1	DNA Restriction Enzymes (Restriction Endonuclease)IBA 08/2003
1	NucleotidesIBA 08/2003
1	1-Octanol (1 Octanol)IBA 11/2002
1	NeurotoxinsIBA 10/2002
1	AlcoholsIBA 10/2002

Therapy/Procedure

1	Long-Term Care 01/2022
1	Therapeutics 01/2019
1	Cognitive Training 01/2019
1	Intraperitoneal Injections 10/2006